Global Neurosciences Institute Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2014
NCT02285959
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Global Neurosciences Institute

Active Ingredients

Drugs in Phase 1 Trials (2)

bevacizumab (avastin) (1 trial)

verapamil (calan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 1)

Ischemia (Phase 1)

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2